France Ultrasound Infertility Diagnosis and Treatment Market by Care Pathway (Infertility Diagnostics, Punction, and Treatment Monitoring) and End User (Public Hospital with Infertility Department, Private Fertility Clinics and Ambulatory Centers): Opport

France Ultrasound Infertility Diagnosis and Treatment Market by Care Pathway (Infertility Diagnostics, Punction, and Treatment Monitoring) and End User (Public Hospital with Infertility Department, Private Fertility Clinics and Ambulatory Centers): Opportunity Analysis and Industry Forecast, 2021–2030

The France ultrasound infertility diagnosis and treatment market was valued at $336.54 million in 2020, and is estimated to reach $522.36 million by 2030, growing at a CAGR of 4.4% from 2021 to 2030.

Infertility in individuals is defined as the inability of the male or female reproductive system to conceive naturally. Ultrasound-guided infertility diagnosis is a technique in which ultrasound waves are used for determination for the cause of infertility in males as well as females. In females, infertility is caused majorly due to blocked fallopian tubes; sexually transmitted infections (STIs); uterine disorders such as endometriosis, septate uterus, and fibroids; and ovarian disorder such as the polycystic ovarian syndrome (PCOS). On the contrary, in males, obstruction of the reproductive tract, testicular impairment, and hormonal misbalance may result in infertility.

Fertility services help treat infertility in men and women. The different forms of fertility treatments available include in vitro fertilization (IVF), fertility testing, intrauterine insemination, and egg freezing & embryo banking. These treatments are often opted by single mothers, the LGBTQ community, and couples who find it hard to procreate. Ultrasound-guided procedures for infertility diagnosis such as hysterosonography, hysterosonosalpyngography, and hysterosalpingo-foam sonography are used to determine the woman's uterus for a variety of issues such as vaginal bleeding, recurrent miscarriages, fibroids, polyps, scar tissue, or other abnormalities.

Hysterosonosalpyngography is used to determine the fallopian tubes blockage. Ultrasound-guided trans-vaginal needle aspiration/biopsy and core-needle testicular biopsy in females and males are the minimally invasive techniques that assess infertility diagnosis. Treatment monitoring service such as the ovulation monitoring is one of the majorly used techniques for predicting the ovulation for conceiving through kits and is less expensive.

The major factors that drive the growth of the ultrasound infertility diagnosis & treatment market include increase in prevalence of infertility rates, rise in trend of delayed pregnancies, surge in the number of median age of first-time mothers, increase in awareness of in vitro fertilization (IVF), and technological advancements for infertility diagnosis. According to the World Bank fertility rate, total (births per woman) in France in 2018 was 1.88, and it reduced to 1.87 in 2019. Infertility affects millions of people of reproductive age worldwide and has an impact on their families and communities. Millions of people of reproductive age around the world are affected by infertility, which has an impact on their families and communities. Thus, increase in infertility rates and reduction of birth rates is expected to drive the market growth.

In addition, surge in adoption of sedentary lifestyle; rise in alcohol, smoking, & tobacco consumption; excessive stress; unhealthy lifestyle; and surge in obesity cases are expected to drive the growth of the ultrasound-guided infertility diagnosis & treatment monitoring services market. For instance, in 2019, according to the World Health Organization (WHO) global report on trends in prevalence of tobacco use 2000–2025, the tobacco use rates across the people in France aged 15 years and older, was estimated to be 36.0 in males and 33.2 in males.

Cigarette smoking rates were estimated to be 33.0 in males and 30.0 in females and about 30.9 in 2018. Thus, such high tobacco consumption and smoking is expected to affect the fertility of males and females, which, in turn, drives the growth of the market in France.

Moreover, according to the Organisation for Economic Co-operation and Development (OECD), about 1 in 10 individuals is obese in France, and almost 40% are overweight (including obese). OECD has estimated that overweight rates will increase by a further 10% within 10 years. In addition, according to the Eurostat in 2019, about 40% of French women were overweight, and among this, about 17% of women were obese. ,. Menstrual disorders and anovulation are more common in overweight women. Women who are overweight or obese are at a higher risk of having a miscarriage. These women have a higher risk of subfecundity and infertility as well as conception, miscarriage, and pregnancy problems. Thus, all these factors notably contribute toward the growth of the France ultrasound infertility diagnosis and treatment market.

Furthermore, technological advancements IVF techniques and frozen embryo transfer boost the market growth. For instance, in June 2021, France’s Lower House of Parliament approved a law that will allow single women and lesbians to access medically assisted reproduction for the first time. Thus, provision of access to fertility treatments such as artificial insemination and IVF is expected to strengthen the growth of the market in France.

However, high cost of infertility diagnosis procedures, risk associated after IVF procedure, and high cost of assisted reproductive technology hinder the market growth. On the contrary, initiatives taken by governments for development of the technology sector in infertility and increase in disposable income level of consumers are expected to offer remunerative opportunities for the market growth.

In addition, surge in demand for advanced technologies in healthcare to enhance efficiency of procedures and smooth delivery of babies is expected to open new avenues for the market growth during the forecast period.

The France ultrasound infertility diagnosis and treatment market is segmented into care pathway and end user. On the basis of care pathway, the market is fragmented into infertility diagnostics, punction, and treatment monitoring. The infertility diagnostics segment is further classified into hysterosonography, hysterosonosalpyngography, and hysterosalpingo-foam sonography (HyFoSy). The punction segment is subsegmented into ultrasound-guided trans-vaginal needle aspiration/biopsy and ultrasound guided core-needle testicular biopsy. Moreover, the treatment monitoring segment comprises frozen embryo transfer services and ovulation monitoring.

Depending on end user, the market is segregated into public hospital with infertility department, private fertility clinics and ambulatory centers. Each end user is further segmented into the care pathway bifurcation of infertility diagnostics, punction, and treatment monitoring.

The major players profiled in the report are American Hospital of Paris, Amp Center St Roch, Amp Natecia Lyon, Centre Chirugical (Pierre Cherest Clinic), Fertility Center-Parsi East, Hospital Cochin, Hospital Group Diaconesses Croix Saint-Simon, Maternité Des Bluets - Hospital Pierre Rouquès, Pointgyn-Pleasure and Ramsay Healthcare Limited (Clinique De La Muette).

KEY BENEFITS FOR STAKEHOLDERS

This report provides an extensive analysis of the current and emerging market trends and dynamics in the France ultrasound infertility diagnosis and treatment market to identify the prevailing opportunities.
This study presents the competitive landscape of the market to predict the competitive environment across the country.
Comprehensive analysis of factors that drive and restrict the market growth is provided.

KEY MARKET SEGMENTS


By Care Pathways

Infertility Diagnostics
Hysterosonography
Hysterosonosalpyngography
Hysterosalpingo-foam Sonography (HyFoSy)
Punction
Ultrasound-guided trans-vaginal Needle Aspiration/Biopsy
Ultrasound-guided core-needle Testicular Biopsy
Treatment Monitoring
Frozen Embryo Transfer
Ovulation Monitoring

By End User

Public Hospital with Infertility Department
Infertility Diagnostics
Punction
Treatment Monitoring
Private Fertility Clinics
Infertility diagnostics
Punction
Treatment Monitoring
Ambulatory Centers
Infertility Diagnostics
Punction
Treatment Monitoring

KEY MARKET PLAYERS

American Hospital of Paris
Amp Center St Roch
Amp Natecia Lyon
Centre Chirugical (Pierre Cherest Clinic)
Fertility Center-Parsi East
Hospital Cochin
Hospital Group Diaconesses Croix Saint-Simon
Maternité Des Bluets - Hospital Pierre Rouquès
Pointgyn-Pleasure
Ramsay Healthcare Limited (Clinique De La Muette)

List of Company Profiles

American Hospital of Paris
Amp Center St Roch
Amp Natecia Lyon
Centre Chirugical (Pierre Cherest Clinic)
Fertility Center-Parsi East
Hospital Cochin
Hospital Group Diaconesses Croix Saint-Simon
Maternité Des Bluets - Hospital Pierre Rouquès
Pointgyn-Pleasure,
Ramsay Healthcare Limited (Clinique De La Muette).